Amendments to the Claims:

1. (~~Original~~Currently Amended)A compound of formula (I),



wherein

m is 1, 2 or 3;

R^1 is methyl, chloro, bromo or fluoro;

R^2 is $-Q^1-Q^2-Q^3-Q^4$ or (C_1-C_6)alkyl,

- said (C_1-C_6)alkyl is substituted with one to three OR^4, $COOR^4$, NR^4R^5, $NRC(=O)R^4$, $C(=O)NR^4R^5$ or $SO_2NR^4R^5$;
- R^4 is (C_1-C_6)alkyl substituted with one to three F, CN, $S(=O)R^6$, SO_3H, SO_2R^6, SR^7, $C(=O)$-NH-SO_2-CH_3, $C(=O)R^7$, $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$, O-$C(=O)NR^7R^8$ or $SO_2NR^7R^8$;
- R^5 is H or (C_1-C_6)alkyl optionally substituted with one to three F, CN, $S(=O)R^6$, SO_3H, SO_2R^6, SR^7, $C(=O)$-NH-SO_2-CH_3, $C(=O)R^7$, $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$, O-$C(=O)NR^7R^8$ or $SO_2NR^7R^8$; or
- said (C_1-C_6)alkyl is
  1) substituted with one to three $OC(=O)R^{4a}$, SR^{4a}, $S(=O)R^3$, $C(=NR^9)R^{4a}$, $C(=NR^9)$-$NR^{4a}R^{5a}$, NR-$C(=NR^9)$-$NR^{4a}R^{5a}$, $NRCOOR^{4a}$, NR-$C(=O)$-$NR^{4a}R^{5a}$, NR-SO_2-$NR^{4a}R^{5a}$, NR-$C(=NR^9)$-R^{4a} or NR-SO_2-R^3; and
  2) optionally substituted with one or two OR^{4a}, $COOR^{4a}$, $C(=O)$-R^{4a}, $NR^{4a}R^{5a}$, $NRC(=O)R^{4a}$, $C(=O)NR^4R^{5a}$ or $SO_2NR^{4a}R^{5a}$;
- R^9 is H, CN, OH, OCH_3, SO_2CH_3, SO_2NH_2 or (C_1-C_6)alkyl; and
- R^3 is (C_1-C_6)alkyl optionally substituted with one to three F, CN, $S(=O)R^6$, SO_3H, SO_2R^6, $C(=O)$-NH-SO_2-CH_3, OR^7, SR^7, $COOR^7$, $C(=O)R^7$, O-$C(=O)NR^7R^8$, NR^7R^8, $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$ or $SO_2NR^7R^8$;

- R^{4a} and R^{5a} are the same or different and are H or $(C_1$-$C_6)$alkyl optionally substituted with one to three F, CN, $S(=O)R^6$, SO_3H, SO_2R^6, $C(=O)$-NH-SO_2-CH_3, OR^7, SR^7, $COOR^7$, $C(=O)R^7$, O-$C(=O)NR^7R^8$, NR^7R^8, $NR'C(=O)R^7$, $NR'SO_2R^6$, $C(=O)NR^7R^8$ or $SO_2NR^7R^8$;

Q^1 is a single bond or $(C_1$-$C_6)$alkylene;

Q^2 is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N;

Q^3 is $(C_1$-$C_6)$alkylene;

Q^4 is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4 -O-, -S-, -S(=O)-, $-SO_2-$ or -N-, said heterocyclyl being optionally substituted with one to three -OR, -NRR', -CN or $-(C_1$-$C_6)$alkyl;

R is H or $(C_1$-$C_6)$alkyl;

R^6 is $(C_1$-$C_6)$alkyl optionally substituted with one or two -OR';

R^7 and R^8 are the same or different and are H or $(C_1$-$C_6)$alkyl optionally substituted with one or two -OR';

R^9 is H, -CN, -OH, $-OCH_3$, $-SO_2CH_3$, $-SO_2NH_2$ or $-(C_1$-$C_6)$alkyl;

R' is H or $(C_1$-$C_6)$alkyl; and

R'' is H or $(C_1$-$C_6)$alkyl;

provided that

1) the atom of Q^2 bound to Q^1 is a carbon atom; and

2) the atom of Q^4 bound to Q^3 is a carbon atom;

or a racemic form, isomer, pharmaceutically acceptable salts, hydrates, solvates and polymorphs ~~derivative~~ thereof.

2. (Original) A compound of claim 1 wherein R^2 is $(C_1$-$C_6)$alkyl substituted with $-OR^4$, $-COOR^4$, $-NR^4R^5$, $NRC(=O)R^4$, $-C(=O)NR^4R^5$ or $-SO_2NR^4R^5$; R^4 is $(C_1$-$C_6)$alkyl substituted with one to three $-S(=O)R^6$, $-SO_2R^6$, $-NR'C(=O)R^7$, $-NR'SO_2R^6$, $-C(=O)NR^7R^8$, $-O$-$C(=O)NR^7R^8$ or $SO_2NR^7R^8$; R^5 is H or $(C_1$-$C_6)$alkyl optionally substituted with one to three $-S(=O)R^6$, $-SO_2R^6$, $-NR'C(=O)R^7$, $-NR'SO_2R^6$, $-C(=O)NR^7R^8$, $-O$-$C(=O)NR^7R^8$ or $SO_2NR^7R^8$; R^6 is $(C_1$-$C_6)$alkyl; and R', R^7 and R^8 are the same or different and are H or $(C_1$-$C_6)$alkyl.

3. (Original) A compound of claim 1 wherein R^2 is (C_1-C_4)alkyl substituted with -NR^4R^5 or -$C(=O)NR^4R^5$; R^4 is (C_1-C_6)alkyl substituted with -$S(=O)CH_3$, -$NHC(=O)CH_3$ or -$C(=O)NR^7R^8$; R^5 is H or methyl; and R^7 and R^8 are the same or different and are H or methyl.

4. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6)alkyl substituted with one to three -$OC(=O)R^{4a}$, -SR^{4a}, -$S(=O)R^3$, -$NRCOOR^{4a}$, -NR-$C(=O)$-$NR^{4a}R^{5a}$, -NR-SO_2-$NR^{4a}R^{5a}$ or -NR-SO_2-R^3; and said (C_1-C_6)alkyl is optionally substituted with -OH or -OCH_3; R is H or CH_3; R^3 is (C_1-C_6)alkyl optionally substituted with one to three -F, -CN, -$S(=O)R^6$, -SO_3H, -SO_2R^6, -$C(=O)$-NH-SO_2-CH_3, -OR^7, -SR^7, -$COOR^7$, -$C(=O)R^7$, -O-$C(=O)NR^7R^8$, -NR^7R^8, -$NR'C(=O)R^7$, -$NR'SO_2R^6$, -$C(=O)NR^7R^8$ or -$SO_2NR^7R^8$; R^{4a} and R^{5a} are the same or different and are H, (C_1-C_6)alkyl optionally substituted with one to three -F, -CN, -$S(=O)R^6$, -SO_3H, -SO_2R^6, -$C(=O)$-NH-SO_2-CH_3, -OR^7, -SR^7, -$COOR^7$, -$C(=O)R^7$, -O-$C(=O)NR^7R^8$, -NR^7R^8, -$NR'C(=O)R^7$, -$NR'SO_2R^6$, -$C(=O)NR^7R^8$ or -$SO_2NR^7R^8$; R^6 is (C_1-C_6)alkyl; and R', R^7 and R^8 are the same or different and are H or (C_1-C_6)alkyl.

5. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6)alkyl substituted with -$S(=O)R^3$; R^3 is (C_1-C_6)alkyl optionally substituted with one to three -$S(=O)R^6$, -SO_2R^6, -NR^7R^8, -OR^7, -$NR'C(=O)R^7$, -$NR'SO_2R^7$; -$C(=O)NR^7R^8$; or -O-$C(=O)NR^7R^8$; R^6 is (C_1-C_6)alkyl; and R', R^7 and R^8 are the same or different and are H or (C_1-C_6)alkyl.

6. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6)alkyl substituted with -$S(=O)R^3$; and R^3 is (C_1-C_6)alkyl, preferably methyl.

7. (Original) A compound of claim 1 wherein R^2 is Q^1-Q^2-Q^3-Q^4; Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom; Q^3 is a linear (C_1-C_4)alkylene group; Q^4 is a 5- or 6-membered aromatic heterocycle comprising one to four nitrogen atoms, said heterocycle being optionally substituted with methyl.

8. (Original) A compound of claim 1 wherein R^2 is Q^1-Q^2-Q^3-Q^4; Q^1 is a single bond; Q^2 is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom; Q^3 is $-CH_2-$; and Q^4 is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl.

9. (Original) A compound of claim 8 wherein R^1 is -Cl or -F.

10. (Original) A compound of claim 8 wherein m is 2.

11. (~~Original~~Currently Amended) A compound according to claim 8 and selected from

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; or

8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy}1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.

12. (~~Original~~Canceled) ~~A method of treating a disease for which PDE7 inhibition therapy is indicated in a mammal comprising administering to said mammal in need thereof a compound of claim 1.~~

13. (~~Original~~Currently Amended) A method of ~~claim 12 wherein said~~ treating a disease is selected from T-cell-related diseases, ~~autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis,~~ osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS),

allergy, ~~inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, pancreatitis,~~ dermatoses, psoriasis, atopic dermatitis, ~~glomerulonephritis, conjunctivitis, autoimmune diabete, graft rejection, epilepsy, muscular atrophy and systemic lupus erythematosus~~ in a mammal comprising administering to said mammal in need thereof, a compound of claim1.

14. (Original) A method of claim 13 wherein said disease is asthma, allergy or atopic dermatitis.

15. (Original) A method of claim 13 wherein said disease is osteoporosis.

16. (Original) A method of claim 13 wherein said disease is cancer.

17. (Original) A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.